Related articles
-
Article
Valeant’s financial restatement begs compliance questions
Valeant Pharmaceuticals’ announced financial restatement raises questions about the drug company’s compliance program and its business model. But it might also serve as an early warning to all publicly listed U.S. companies about the increased room for misjudging the booking of sales once FASB rolls out its new revenue recognition ...
-
PodcastStudy: Compliance managers must set rules in race to adopt AI agents and copilots
More than half of all compliance teams are “actively using” or “piloting” AI applications, according to a Moody’s report. While most are focusing on streamlining routine tasks, some are developing AI agents and asking vital questions about AI decision-making.
-
OpinionAI adoption without trust: A call for compliance professionals
Employees are adopting AI faster than companies can build policies, governance, and training. That gap creates compliance exposure in areas from data privacy to shadow IT to workplace equity.